← Back to Search

Monoclonal Antibodies

RO7444973 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests a new drug, RO7444973, in patients with advanced solid tumors that have a specific genetic marker. The drug aims to help the immune system identify and destroy these cancer cells.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part III: Recommended Phase 2 Dose (RP2D) ExpansionExperimental Treatment2 Interventions
Based on emerging data from Part II, an RP2D and dosing regimen will be further investigated in Part III.
Group II: Part II: Multiple Participant Cohort (MPC) Dose EscalationExperimental Treatment2 Interventions
In Part II, RO7444973 is administered IV Q3W at a fixed dose in multiple participants per dose level. Step-up dosing may also be explored.
Group III: Part I: Single Participant Cohort (SPC) Dose EscalationExperimental Treatment2 Interventions
In Part I, RO7444973 is administered intravenously (IV) every 3 weeks (Q3W) at a fixed dose in a single participant per dose level.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tocilizumab
2012
Completed Phase 4
~1840

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,444 Previous Clinical Trials
1,093,099 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,212 Previous Clinical Trials
892,393 Total Patients Enrolled
~6 spots leftby Sep 2025